1. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial Verstovsek, Srdan; Mesa, Ruben A.; Gotlib, Jason; Gupta, Vikas; DiPersio, John F.; Catalano, John V.; Deininger, Michael W. N.; Miller, Carole B.; Silver, Richard T.; Talpaz, Moshe; Winton, Elliott F.; Harvey, Jimmie H.; Arcasoy, Murat O.; Hexner, Elizabeth O.; Lyons, Roger M.; Paquette, Ronald; Raza, Azra; Jones, Mark; Kornacki, Deanna; Sun, Kang; Kantarjian, Hagop 2017 Articles MyelofibrosisJAK-STAT pathwayClinical trialsHematological oncology